Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
Compose a Response to This Article
Other responses
No responses have been published for this article.